US FTC sues to block Illumina/Pacific Biosciences
The US Federal Trade Commission has issued an administrative complaint alleging that a merger in the DNA sequencing industry will maintain Illumina’s monopoly by eliminating a nascent competitive threat.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.